Dr. Duke A. Phan, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Geisel School of Medicine at Dartmouth (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 274
Licensed in California since 1992, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Geisel School of Medicine at Dartmouth
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
CA license A51193 (first issued 1992; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 274
- Services billed
- 1,183
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 290 | 57 |
| Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | 102 | 54 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 65 | 65 |
| Established patient office or other outpatient visit, 30-39 minutes | 44 | 41 |
| Established patient office or other outpatient visit, 40-54 minutes | 41 | 40 |
| New patient office or other outpatient visit, 60-74 minutes | 36 | 36 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 32 | 16 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 20 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Donepezil Hcl Other prescribers in Fountain Valley, CA | 335 |
| Memantine Hcl Other prescribers in Fountain Valley, CA | 168 |
| Nortriptyline Hcl Other prescribers in Fountain Valley, CA | 126 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Fountain Valley, CA | 112 |
| Gabapentin Other prescribers in Fountain Valley, CA | 110 |
| Levetiracetam Other prescribers in Fountain Valley, CA | 104 |
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Fountain Valley, CA | 103 |
| Mirtazapine Other prescribers in Fountain Valley, CA | 95 |
| Entacapone | 84 |
| Quetiapine Fumarate Other prescribers in Fountain Valley, CA | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 7 payments worth $744 in total to this clinician.
| Neurocrine Biosciences, Inc. | $128 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $124 |
| Alexion Pharmaceuticals, Inc. | $120 |
| Pfizer Inc. | $120 |
| Argenx US, Inc. | $115 |
| Lilly USA, LLC | $112 |
| Eisai Inc. | $25.89 |
| Food and Beverage | $744 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.